Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 18;63(1):32.
doi: 10.1186/s42358-023-00310-6.

The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness

Qiaoli Hua #  1   2   3 , Xusheng Liu #  2   4   5 , Yang Luo  6 , Yujie Lin  1 , Kairong Zheng  7   8 , Ai Xia  1   8 , Qianchun Yang  9   10   11   12
Affiliations

The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness

Qiaoli Hua et al. Adv Rheumatol. .

Abstract

Background: Gout is a common inflammatory arthritis caused by increased serum uric acid levels. Untreated or insufficiently treated gout can lead to deposition of monosodium urate crystals in joints, cartilage, and kidneys. Although Tongfengding capsules, a Chinese patent medicine, have long been used to treat gout, their effects and safety have not been reviewed systematically. This study evaluated its efficacy and safety for gout in adults.

Methods: Randomized controlled trials involving Tongfengding capsule for gout in adults were searched from PubMed, EMBASE, Cochrane Central Register of Controlled Trials, CBM, CNKI, and VIP databases, and analyzed using the Cochrane Handbook criteria. The primary outcome measures were the total effective rate. The secondary outcome measures including the blood uric acid (BUA), 24-h urinary total protein (24-h UTP), blood urea nitrogen (BUN), interleukin (IL)-6, IL-8, tumor necrosis factor-alpha (TNF-α) and adverse effects. The risk of bias was evaluated in all included studies. RevMan ver. 5.3.5 and GRADE profiler was used for data analysis and assessing the quality of evidence, respectively.

Results: Six studies (n = 607 Chinese participants) were included. Tongfengding capsules plus conventional treatment significantly increased the total effective rate (RR 1.21, 95% CI 1.11-1.33), while reducing the BUA (MD - 66.05 µmol/L, 95% CI - 81.26 to - 50.84), 24-h UTP (MD - 0.83 g/24 h, 95% CI - 0.96 to - 0.70), BUN (MD - 0.90 mmol/L, 95% CI - 1.60 to - 0.20), IL-6 (MD - 6.99 ng/L, 95% CI - 13.22 to - 0.75), IL-8 (MD - 12.17 ng/L, 95% CI - 18.07 to - 6.27), TNF-α (MD - 8.50 ng/L, 95% CI - 15.50 to - 1.51), and adverse effects (RR 0.21, 95% CI 0.04-0.95).

Conclusion: Tongfengding capsules plus conventional treatment is safe and beneficial for adults with gout compared with conventional treatment.

Keywords: Chinese patent medicine; Gout; Randomized controlled trials; Systematic review; Tongfengding capsule.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Pérez-Ruiz F, Jansen T, Tausche AK, et al. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drug in Context. 2019;8:212581. https://doi.org/10.7573/dic.212581 . - DOI
    1. Lee HE, Yang G, Park YB, et al. Epigallocatechin-3-gallate prevents acute gout by suppressing NLRP3 inflammasome activation and mitochondrial DNA synthesis. Molecules. 2019;24(11):2138. https://doi.org/10.3390/molecules24112138 . - DOI - PubMed - PMC
    1. Liu X, Liu K, Sun Q, et al. Efficacy and safety of febuxostat for treating hyperuricemia in patients with chronic kidney disease and in renal transplant recipients: a systematic review and meta-analysis. Exp Ther Med. 2018;16(3):1859–65. - PubMed - PMC
    1. Zhou L, Liu L, Liu XY, et al. Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. PLOS ONE. 2014;9(1):e85008. - DOI - PubMed - PMC
    1. Sinan Deveci O, Kabakci G, Okutucu S, et al. The association between serum uric acid level and coronary artery disease. Int J Clin Pract. 2010;64:900–7. - DOI - PubMed

Publication types